The intern will be producing a therapeutic protein, i.e. ‘biologic’ (BMP2) using mutated bacterial plasmids as the bio-factory. The intern will create a sequence of DNA to be transformed into E. coli cells (BL21). The cells will be grown up in the lab, and studied for enhanced clinical efficacy. Proteins will be affinity purified and the resulting BMP2 variants will be tested in lab bioactivity assays. With a more potent mutant BMP2, our partner will be able to increase the number of successful implantation and reconstruction services they offer as a smaller physical quantity of BMP2 will reduce illicit adverse immune events.
Dr. Illimar Altosaar
Dr Hassan Ghaderi Moghadam Professional Corporation
Biochemistry / Molecular biology
University of Ottawa
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.